The importance of controlling postprandial glucose in patients with type 1 and type 2 diabetes has received increasing attention. A number of drugs targeted to this goal are in development or have recently been introduced. The replacement of secreted insulin with regular insulin or short acting insulin analogs has proved to be helpful in both type I and type II patients. Short acting insulin secretagogues offer potential to improve control in type II diabetes. Alpha glucosidase inhibitors can be used to titrate carbohydrate load in both types of diabetes. Amylin and GLP-1 offer possible physiological solutions to achieving better glucose control. The availability of a variety of different agents to treat postprandial glucose give new impetus to the possibility of achieving near normal or euglycemia in patients with diabetes. How to best maximize the potential of these agents still remains a challenge.